**List of Publications:**

1. Mattei G, Di Patria V, Tirella A, Alaimo A, **Elia G**, Corti A, Paolicchi A, Ahluwalia A. Mechanostructure and composition of highly reproducible decellularized liver matrices. Acta Biomater. 2014;10(2):875
2. **Elia G**. Interferon-γ-Inducible chemokines in Systemic Lupus Erythematosus. Clin Ter. 2015;166(1):e41-6.
3. **Elia G**. Dermatomyositis and chemokines. Clin Ter. 2015;166(2):e118-21.
4. Fallahi P, Ferrari SM, **Elia G**, Nasini F, Colaci M, Giuggioli D, Vita R, Benvenga S, Ferri C, Antonelli A. Novel Therapies for Thyroid Autoimmune Diseases. Expert Rev Clin Pharmacol. 2016;9(6):853-61.
5. Fallahi P, Ferrari SM, Ruffilli I, **Elia G**, Giuggioli D, Colaci M, Ferri C, Antonelli A. Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up. Autoimmun Rev. 2016;15(7):747-51
6. Fallahi P, Ferrari SM, Ruffilli I, **Elia G**, Biricotti M, Vita R, Benvenga S, Antonelli A. The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients. Autoimmun Rev. 2016;15(12):1125-1128.
7. Fallahi P, **Elia G**, Bonatti A. Leishmaniasis and IFN-γ dependent chemokines. Clin Ter. 2016;167(5):e117-e122.
8. Fallahi P, **Elia G**. Interferon-γ-induced protein 10 in Dengue Virus infection. Clin Ter. 2016;167(6):e186-e191.
9. Fallahi P, Ferrari SM, Ruffilli I, **Elia G**, Miccoli M, Sedie AD, Riente L, Antonelli A. Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study. Immunol Res. 2017 Jun;65(3):681-686.
10. **Elia G**, Fallahi P. Hepatocellular carcinoma and CXCR3 chemokines: a narrative review. Clin Ter. 2017 Jan-Feb;168(1):e37-e41.
11. Fallahi P, **Elia G**, Bonatti A. Interferon-γ-induced protein 10 in Lyme disease. Clin Ter. 2017 Mar-Apr;168(2):e146-e150.;168(1):e37-e41.
12. Ferrari SM, **Elia G**, Virili C, Centanni M, Antonelli A, Fallahi P. Systemic Lupus Erythematosus and Thyroid Autoimmunity. Front Endocrinol (Lausanne). 2017 Jun 19;8:138.
13. Ferrari SM, **Elia G**, Piaggi S, Baldini E, Ulisse S, Miccoli M, Materazzi G, Antonelli A, Fallahi P. CCL2 is Modulated by Cytokines and PPAR-g in Anaplastic Thyroid Cancer. Anticancer Agents Med Chem. 2018;18(3):458-466.
14. Fallahi P, **Elia G**, Foddis R, Cristaudo A, Antonelli A. High risk of brain tumors in military personnel: a case control study. Clin Ter. 2017 Nov-Dec;168(6):e376-e379.
15. Ferrari SM, Bocci G, Di Desidero T, **Elia G**, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep. 2018 May;39(5):2225-2234.
16. Ferrari SM, Bocci G, Di Desidero T, Ruffilli I, **Elia G**, Ragusa F, Fioravanti A, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. Oncol Rep. 2018 May;39(5):2306-2314.
17. Fallahi P, Foddis R, **Elia G**, Ragusa F, Patrizio A, Benvenga S, Cristaudo A, Antonelli A, Ferrari SM. Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells. Oncol Rep. 2018 May;39(5):2422-2426.
18. Fallahi P, Foddis R, **Elia G**, Ragusa F, Patrizio A, Guglielmi G, Frenzilli G, Benvenga S, Cristaudo A, Antonelli A, Ferrari SM. Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide. Mol Med Rep. 2018 May;17(5):6914-6918.
19. Fallahi P, Foddis R, **Elia G**, Ragusa F, Patrizio A, Frenzilli G, Benvenga S, Cristaudo A, Antonelli A, Ferrari SM. Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells. Mol Med Rep. 2018 May;17(5):7415-7420.
20. Fallahi P, Foddis R, **Elia G**, Ragusa F, Patrizio A, Benvenga S, Cristaudo A, Antonelli A, Ferrari SM. CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide. Mol Med Rep. 2018 Aug;18(2):1798-1803.
21. Fallahi P, Ruffilli I, **Elia G**, Ragusa F, Ulisse S, Baldini E, Miccoli M, Materazzi G, Antonelli A, Ferrari SM. Novel treatment options for anaplastic thyroid cancer. Expert Rev Endocrinol Metab. 2017 Jul;12(4):279-288.
22. Ferrari SM, Fallahi P, Ruffilli I, **Elia G**, Ragusa F, Paparo SR, Ulisse S, Baldini E, Giannini R, Miccoli P, Antonelli A, Basolo F. Molecular testing in the diagnosis of differentiated thyroid carcinomas. Gland Surg. 2018 Aug;7(Suppl 1): S19-S29.
23. **Elia G**, Guglielmi G. CXCL9 chemokine in ulcerative colitis. Clin Ter. 2018 Sep-Oct;169(5):e235-e241.
24. Ferrari SM, **Elia G**, Ragusa F, Paparo SR, Caruso C, Benvenga S, Fallahi P, Antonelli A. The protective effect of myo-inositol on human thyrocytes. Rev Endocr Metab Disord. 2018 Dec;19(4):355-362.
25. Fallahi P, Ferrari SM, **Elia G**, Ragusa F, Paparo SR, Caruso C, Guglielmi G, Antonelli A. Myo-inositol in autoimmune thyroiditis, and hypothyroidism. Rev Endocr Metab Disord. 2018 Dec;19(4):349-354.
26. **Elia G**. MIG in psoriatic arthritis. Clin Ter. 2018 Nov-Dec;169(6):e297-e302.
27. **Elia G**. MIG Th1 chemokine in Vitiligo. Clin Ter. 2018 Nov-Dec;169(6):e303-e307.
28. Fallahi P, Ferrari SM, Piaggi S, Luconi M, Cantini G, Gelmini S, **Elia G**, Ruffilli I, Antonelli A. The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results. Immunol Res. 2018;66(6):710-722.
29. Ferrari SM, La Motta C, **Elia G**, Ragusa F, Ruffilli I, Quattrini L, Paparo SR, Piaggi S, Patrizio A, Ulisse S, Baldini E, Materazzi G, Fallahi P, Antonelli A. Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration. Front Endocrinol (Lausanne). 2018 Dec 18;9:764.
30. Ferrari SM, Fallahi P, La Motta C, **Elia G**, Ragusa F, Ruffilli I, Patrizio A, Baldini E, Ulisse U, Antonelli A. (2019) Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. Expert Review of Precision Medicine and Drug Development. 2019 4:1,37-49.
31. Ferrari SM, Fallahi P, Ruffilli I, **Elia G**, Ragusa F, Benvenga S, Antonelli A. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series. Autoimmun Rev. 2019 Mar;18(3):287-292.
32. Ferrari SM, Fallahi P, **Elia G**, Ragusa F, Ruffilli I, Patrizio A, Galdiero MR, Baldini E, Ulisse S, Marone G, Antonelli A. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. Int J Mol Sci. 2019;20(10):2560.
33. Ferrari SM, Fallahi P, **Elia G**, Ragusa F, Ruffilli I, Paparo SR, Antonelli A. Thyroid autoimmune disorders and cancer. Semin Cancer Biol. 2020;64:135-146.
34. Ferrari SM, Ruffilli I, **Elia G**, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Antonelli A, Fallahi P. Chemokines in hyperthyroidism. J Clin Transl Endocrinol. 2019 May 17;16:100196.
35. Antonelli A, Ferrari SM, **Elia G**, Patrizio A, Fallahi P. Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up. Gland Surg. 2019 Jun;8(3):298-300.
36. Ferrari SM, Fallahi P, Ruffilli I, **Elia G**, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Colaci M, Giuggioli D, Ferri C, Antonelli A. Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C? J Immunol Res. 2019 Aug 8;2019:5878960.
37. Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, **Elia G**, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Varricchi G, Marone G, Antonelli A. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int J Mol Sci. 2019;20(18):4413.
38. Fallahi P, Ferrari SM, **Elia G**, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Materazzi G, Antonelli A. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes. Cancer Management and Research. 2019 Aug;11:7893-7907.
39. Ragusa F, Fallahi P, **Elia G**, Gonnella D, Paparo SR, Giusti C, Churilov LP, Ferrari SM, Antonelli A. Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab. 2019 Dec;33(6):101367.
40. Ferrari SM, Fallahi P, **Elia G**, Ragusa F, Camastra S, Paparo SR, Giusti C, Gonnella D, Ruffilli I, Shoenfeld Y, Antonelli A. Novel therapies for thyroid autoimmune diseases: An update. Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101366.
41. Fallahi P, Ferrari SM, Ragusa F, Ruffilli I, **Elia G**, Paparo SR, Antonelli A. Th1 Chemokines in Autoimmune Endocrine Disorders. J Clin Endocrinol Metab. 2020; Apr 1;105(4):dgz289.
42. Fallahi P, **Elia G**, Ragusa F, Ruffilli I, Camastra S, Giusti C, Paparo SR, Gonnella D, Shoenfeld Y, Ferrari SM, Antonelli A. The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases. Best Pract Res Clin Endocrinol Metab. 2019 Dec;33(6):101372.
43. Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo SR, Ruffilli I, Varricchi G, Fallahi P, Antonelli A. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101370.
44. Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Novel treatments for anaplastic thyroid carcinoma. Gland Surg. 2020 Jan;9(Suppl 1):S28-S42.
45. Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Gonnella D, Giusti C, Virili C, Centanni M, Shoenfeld Y, Ferrari SM. Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101388.
46. Benvenga S, Elia G, Ragusa F, Paparo SR, Sturniolo MM, Ferrari SM, Antonelli A, Fallahi P. Endocrine disruptors and thyroid autoimmunity. Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101377.
47. Antonelli A, Ferrari SM, Ragusa F, Elia G, Paparo SR, Ruffilli I, Patrizio A, Giusti C, Gonnella D, Cristaudo A, Foddis R, Shoenfeld Y, Fallahi P. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101387.
48. Benvenga S, Ferrari SM, **Elia G**, Ragusa F, Patrizio A, Paparo SR, Camastra S, Bonofiglio D, Antonelli A, Fallahi P. Nutraceuticals in Thyroidology: A Review of in Vitro, and in Vivo Animal Studies. Nutrients. 2020 May 8;12(5):E1337.
49. Fallahi P, Ferrari SM, **Elia G**, Ragusa F, Patrizio A, Paparo SR, Marone G, Galdiero MR, Guglielmi G, Foddis R, Cristaudo A, Antonelli A. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Semin Cancer Biol. 2020 Jun 20:S1044-579X(20)30149-8. Epub ahead of print.
50. Antonelli A, **Elia G**, Ferrari SM, Foddis R, De Marco S, Cristaudo A, Fallahi P. The Covid-19, Epidemiology, Clinic and Prevention. Curr Genomics. 2020 Apr;21(3):157.
51. Fallahi P, Ferrari SM, **Elia G**, Ragusa F, Paparo SR, Camastra S, Mazzi V, Miccoli M, Benvenga S, Antonelli A. THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors. Eur J Endocrinol. 2020 Oct 1:EJE-20-0683.R2.
52. Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, **Elia G**, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol. 2020 Nov 26:S1044-579X(20)30249-2.
53. Fallahi P, Ferrari SM, **Elia G**, Ragusa F, Paparo SR, Antonelli A. L-T4 Therapy in Enteric Malabsorptive Disorders. Front Endocrinol (Lausanne). 2021 Feb 23;12:626371.
54. Antonelli A, **Elia G**, Ragusa F, Paparo SR, Cavallini G, Benvenga S, Ferrari SM, Fallahi P. The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine. Front Endocrinol (Lausanne). 2021 Mar 10;12:633587.
55. Fallahi P, Ferrari SM, **Elia G**, Ragusa F, Paparo SR, Patrizio A, Camastra S, Miccoli M, Cavallini G, Benvenga S, Antonelli A. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy. Front Endocrinol (Lausanne). 2021 Apr 16;12:654473.